SCHEMBL24978697

SCHEMBL24978697

O=C(COCc1ccccc1)Nc1cnc(Cl)nc1Cl

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK1D P48730 2/20 0.49
ADORA3 P0DMS8 1/20 0.49
ADORA2A P29274 1/20 0.49
ADORA1 P30542 1/20 0.49
CETP P11597 1/20 0.44
PTPRC P08575 1/20 0.44
PTPN1 P18031 1/20 0.44
NAMPT P43490 1/20 0.43
RAB9A P51151 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
ALDH1A1 P00352 1/20 0.43
EGFR P00533 2/20 0.42
NPC1 O15118 1/20 0.42
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
KDM4E B2RXH2 1/20 0.41
POLB P06746 1/20 0.41
PIN1 Q13526 1/20 0.41
HTT P42858 1/20 0.40
NR4A1 P22736 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24978703 0.86 CSNK1D (0.46) CSNK1DADORA3ADORA2AADORA1CETP
SCHEMBL28420803 0.83 RAB9A (0.62) RAB9ASMN1; SMN2ALDH1A1NPC1KDM4E
SCHEMBL23331269 0.81 MEN1 (0.64) RAB9ASMN1; SMN2ALDH1A1NPC1MEN1
SCHEMBL16709304 0.78 ADORA3 (0.47) CSNK1DADORA3ADORA2AADORA1CETP
SCHEMBL16709314 0.78 CSNK1D (0.45) CSNK1DADORA3ADORA2AADORA1CETP
SCHEMBL23330674 0.77 ALDH1A1 (0.48) SMN1; SMN2ALDH1A1KMT2AKDM4EPOLB
SCHEMBL28597048 0.77 NPC1 (0.64) CSNK1DADORA3ADORA2AADORA1PTPRC
SCHEMBL23330868 0.77 CHEK1 (0.44) NAMPTSMN1; SMN2ALDH1A1POLBHTT
SCHEMBL16014036 0.76 ADORA3 (0.53) CSNK1DADORA3ADORA2AADORA1CETP
SCHEMBL24978704 0.74 CSNK1D (0.41) CSNK1DADORA3ADORA2AADORA1CETP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230028221-A1 EED INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF JING MEDICINE TECHNOLOGY (SHANGHAI) LTD. (CN) 2023-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230028221-A1 EED INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF CYP4F11, CYP4A11, HSD11B1 CSNK1D 410/4885ADORA3 4007/4885ADORA2A 4403/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.